{"id":58859,"date":"2026-03-05T15:49:43","date_gmt":"2026-03-05T07:49:43","guid":{"rendered":"https:\/\/flcube.com\/?p=58859"},"modified":"2026-03-05T15:50:19","modified_gmt":"2026-03-05T07:50:19","slug":"novo-nordisks-cagrisema-fails-non-inferiority-test-against-lillys-zepbound-in-phase-iii-redefine-4-trial-23-vs-25-5-weight-loss","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58859","title":{"rendered":"Novo Nordisk&#8217;s CagriSema Fails Non\u2011Inferiority Test Against Lilly&#8217;s Zepbound in Phase III REDEFINE 4 Trial \u2013 23% vs. 25.5% Weight Loss"},"content":{"rendered":"\n<p><strong>Novo Nordisk A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) announced that its <strong>Phase III REDEFINE 4 study<\/strong> (NCT06131437) <strong>failed to meet its primary endpoint<\/strong>, with <strong>CagriSema unable to demonstrate non\u2011inferiority<\/strong> to <strong>Eli Lilly&#8217;s Zepbound (tirzepatide)<\/strong> in weight\u2011loss efficacy after 84 weeks of treatment. The setback raises questions about CagriSema&#8217;s competitive positioning in the intensifying obesity pharmacotherapy market ahead of its anticipated U.S. regulatory filing.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>CagriSema (2.4\u202fmg)<\/th><th>Zepbound (15\u202fmg)<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary: Weight Loss (84\u202fweeks)<\/strong><\/td><td>23.0%<\/td><td>25.5%<\/td><td><strong>Failed non\u2011inferiority<\/strong><\/td><\/tr><tr><td><strong>Treatment Regimen Estimand<\/strong><\/td><td>20.2%<\/td><td>23.6%<\/td><td>Gap widens with adherence adjustment<\/td><\/tr><tr><td><strong>Baseline Weight<\/strong><\/td><td>114.2\u202fkg (mean)<\/td><td>114.2\u202fkg (mean)<\/td><td>Matched population<\/td><\/tr><tr><td><strong>Study Duration<\/strong><\/td><td>84\u202fweeks<\/td><td>84\u202fweeks<\/td><td>Open\u2011label, randomized controlled<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-results\">Clinical Trial Results<\/h2>\n\n\n\n<p><strong>Study Design:<\/strong> 809 obese patients with \u22651 comorbidity; open\u2011label, active\u2011controlled vs. tirzepatide 15\u202fmg<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-mechanism\">Product Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Composition:<\/strong> Fixed\u2011dose combination (FDC) of <strong>cagrilintide 2.4\u202fmg<\/strong> (long\u2011acting amylin analogue) + <strong>semaglutide 2.4\u202fmg<\/strong> (GLP\u20111 receptor agonist)<\/li>\n\n\n\n<li><strong>Dosing:<\/strong> Once\u2011weekly subcutaneous injection<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Dual\u2011hormone approach targeting satiety (amylin) and glycemic\/energy regulation (GLP\u20111)<\/li>\n\n\n\n<li><strong>Prior Efficacy:<\/strong> REDEFINE 1\/2 trials showed <strong>20.4% weight loss at 68\u202fweeks<\/strong> vs. 3.0% placebo (baseline 236\u202flbs)<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> <strong>BLA submitted December 2025<\/strong> (U.S.); FDA review ongoing with REDEFINE 4 data now part of submission<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-impact-amp-market-analysis\">Competitive Impact &amp; Market Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Efficacy Gap<\/strong><\/td><td>2.5\u202fpercentage\u2011point deficit vs. Zepbound may limit formulary positioning and pricing power<\/td><\/tr><tr><td><strong>Commercial Risk<\/strong><\/td><td>Lilly&#8217;s Zepbound (tirzepatide) retains efficacy leadership; CagriSema may compete on tolerability\/safety profile rather than headline weight loss<\/td><\/tr><tr><td><strong>Pipeline Pressure<\/strong><\/td><td>Novo Nordisk&#8217;s obesity portfolio increasingly dependent on <strong>amylin monotherapy (petrelintide)<\/strong> and <strong>next\u2011gen oral GLP\u20111<\/strong> programs<\/td><\/tr><tr><td><strong>Investor Sentiment<\/strong><\/td><td>NVO shares expected to face pressure; Street consensus had modeled CagriSema as $5\u20138\u202fbillion peak product<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Response:<\/strong> Management emphasized <strong>tolerability advantages<\/strong> (lower GI discontinuation rates in prior trials) and <strong>preservation of lean muscle mass<\/strong> as differentiation factors; full REDEFINE 4 safety data pending<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> FDA may still approve based on REDEFINE 1\/2 efficacy + acceptable safety; label likely to exclude superiority claim vs. tirzepatide<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-pipeline-adjustments\">Forward\u2011Looking Pipeline Adjustments<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Label Strategy:<\/strong> Expect &#8220;alternative option&#8221; positioning rather than &#8220;best\u2011in\u2011class&#8221; messaging<\/li>\n\n\n\n<li><strong>Pricing Power:<\/strong> Reduced ability to command premium over Zepbound; potential for parity or discount contracting<\/li>\n\n\n\n<li><strong>Combination Studies:<\/strong> Novo Nordisk may accelerate <strong>triple\u2011agonist<\/strong> (GLP\u20111\/GIP\/amylin) programs to reclaim efficacy leadership<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory outcomes, commercial projections, and competitive dynamics for CagriSema. Actual results may differ due to FDA review decisions, market adoption patterns, and ongoing clinical data disclosures.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk A\/S (NYSE: NVO) announced that its Phase III REDEFINE 4 study (NCT06131437) failed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58860,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,199,148,860,86],"class_list":["post-58859","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-eli-lilly","tag-novo-nordisk","tag-nyse-nvo","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk&#039;s CagriSema Fails Non\u2011Inferiority Test Against Lilly&#039;s Zepbound in Phase III REDEFINE 4 Trial \u2013 23% vs. 25.5% Weight Loss - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced that its Phase III REDEFINE 4 study (NCT06131437) failed to meet its primary endpoint, with CagriSema unable to demonstrate non\u2011inferiority to Eli Lilly&#039;s Zepbound (tirzepatide) in weight\u2011loss efficacy after 84 weeks of treatment. The setback raises questions about CagriSema&#039;s competitive positioning in the intensifying obesity pharmacotherapy market ahead of its anticipated U.S. regulatory filing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58859\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk&#039;s CagriSema Fails Non\u2011Inferiority Test Against Lilly&#039;s Zepbound in Phase III REDEFINE 4 Trial \u2013 23% vs. 25.5% Weight Loss\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced that its Phase III REDEFINE 4 study (NCT06131437) failed to meet its primary endpoint, with CagriSema unable to demonstrate non\u2011inferiority to Eli Lilly&#039;s Zepbound (tirzepatide) in weight\u2011loss efficacy after 84 weeks of treatment. The setback raises questions about CagriSema&#039;s competitive positioning in the intensifying obesity pharmacotherapy market ahead of its anticipated U.S. regulatory filing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58859\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T07:49:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-05T07:50:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0505.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58859#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58859\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk&#8217;s CagriSema Fails Non\u2011Inferiority Test Against Lilly&#8217;s Zepbound in Phase III REDEFINE 4 Trial \u2013 23% vs. 25.5% Weight Loss\",\"datePublished\":\"2026-03-05T07:49:43+00:00\",\"dateModified\":\"2026-03-05T07:50:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58859\"},\"wordCount\":417,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58859#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0505.webp\",\"keywords\":[\"Clinical trial results\",\"Eli Lilly\",\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58859#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58859\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58859\",\"name\":\"Novo Nordisk's CagriSema Fails Non\u2011Inferiority Test Against Lilly's Zepbound in Phase III REDEFINE 4 Trial \u2013 23% vs. 25.5% Weight Loss - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58859#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58859#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0505.webp\",\"datePublished\":\"2026-03-05T07:49:43+00:00\",\"dateModified\":\"2026-03-05T07:50:19+00:00\",\"description\":\"Novo Nordisk A\\\/S (NYSE: NVO) announced that its Phase III REDEFINE 4 study (NCT06131437) failed to meet its primary endpoint, with CagriSema unable to demonstrate non\u2011inferiority to Eli Lilly's Zepbound (tirzepatide) in weight\u2011loss efficacy after 84 weeks of treatment. The setback raises questions about CagriSema's competitive positioning in the intensifying obesity pharmacotherapy market ahead of its anticipated U.S. regulatory filing.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58859#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58859\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58859#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0505.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0505.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk's CagriSema Fails Non\u2011Inferiority Test Against Lilly's Zepbound in Phase III REDEFINE 4 Trial \u2013 23% vs. 25.5% Weight Loss\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58859#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk&#8217;s CagriSema Fails Non\u2011Inferiority Test Against Lilly&#8217;s Zepbound in Phase III REDEFINE 4 Trial \u2013 23% vs. 25.5% Weight Loss\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk's CagriSema Fails Non\u2011Inferiority Test Against Lilly's Zepbound in Phase III REDEFINE 4 Trial \u2013 23% vs. 25.5% Weight Loss - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk A\/S (NYSE: NVO) announced that its Phase III REDEFINE 4 study (NCT06131437) failed to meet its primary endpoint, with CagriSema unable to demonstrate non\u2011inferiority to Eli Lilly's Zepbound (tirzepatide) in weight\u2011loss efficacy after 84 weeks of treatment. The setback raises questions about CagriSema's competitive positioning in the intensifying obesity pharmacotherapy market ahead of its anticipated U.S. regulatory filing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58859","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk's CagriSema Fails Non\u2011Inferiority Test Against Lilly's Zepbound in Phase III REDEFINE 4 Trial \u2013 23% vs. 25.5% Weight Loss","og_description":"Novo Nordisk A\/S (NYSE: NVO) announced that its Phase III REDEFINE 4 study (NCT06131437) failed to meet its primary endpoint, with CagriSema unable to demonstrate non\u2011inferiority to Eli Lilly's Zepbound (tirzepatide) in weight\u2011loss efficacy after 84 weeks of treatment. The setback raises questions about CagriSema's competitive positioning in the intensifying obesity pharmacotherapy market ahead of its anticipated U.S. regulatory filing.","og_url":"https:\/\/flcube.com\/?p=58859","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-05T07:49:43+00:00","article_modified_time":"2026-03-05T07:50:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0505.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58859#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58859"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk&#8217;s CagriSema Fails Non\u2011Inferiority Test Against Lilly&#8217;s Zepbound in Phase III REDEFINE 4 Trial \u2013 23% vs. 25.5% Weight Loss","datePublished":"2026-03-05T07:49:43+00:00","dateModified":"2026-03-05T07:50:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58859"},"wordCount":417,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58859#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0505.webp","keywords":["Clinical trial results","Eli Lilly","Novo Nordisk","NYSE: NVO","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58859#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58859","url":"https:\/\/flcube.com\/?p=58859","name":"Novo Nordisk's CagriSema Fails Non\u2011Inferiority Test Against Lilly's Zepbound in Phase III REDEFINE 4 Trial \u2013 23% vs. 25.5% Weight Loss - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58859#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58859#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0505.webp","datePublished":"2026-03-05T07:49:43+00:00","dateModified":"2026-03-05T07:50:19+00:00","description":"Novo Nordisk A\/S (NYSE: NVO) announced that its Phase III REDEFINE 4 study (NCT06131437) failed to meet its primary endpoint, with CagriSema unable to demonstrate non\u2011inferiority to Eli Lilly's Zepbound (tirzepatide) in weight\u2011loss efficacy after 84 weeks of treatment. The setback raises questions about CagriSema's competitive positioning in the intensifying obesity pharmacotherapy market ahead of its anticipated U.S. regulatory filing.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58859#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58859"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58859#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0505.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0505.webp","width":1080,"height":608,"caption":"Novo Nordisk's CagriSema Fails Non\u2011Inferiority Test Against Lilly's Zepbound in Phase III REDEFINE 4 Trial \u2013 23% vs. 25.5% Weight Loss"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58859#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk&#8217;s CagriSema Fails Non\u2011Inferiority Test Against Lilly&#8217;s Zepbound in Phase III REDEFINE 4 Trial \u2013 23% vs. 25.5% Weight Loss"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0505.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58859"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58859\/revisions"}],"predecessor-version":[{"id":58862,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58859\/revisions\/58862"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58860"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}